Acadia (ACAD) shares more than triple in value after being freed from a trading halt following...
Acadia (ACAD) shares more than triple in value after being freed from a trading halt following news that its pimavanserin drug reduced psychotic episodes in patients with Parkinson's disease compared with a placebo in a Phase III trial. Acadia now needs to conduct another late-stage study to confirm the results - two similar trials failed to show a substantial fall in psychotic episodes.
From other sites
at Nasdaq.com (Mar 27, 2015)
at 4-traders.com (Mar 23, 2015)
at Zacks.com (Mar 13, 2015)
at MarketWatch.com (Mar 11, 2015)
at CNBC.com (Mar 11, 2015)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs